Can we use statins to prevent stroke in Fabry disease?
- 204 Downloads
Fabry disease is a rare, X-linked lysosomal storage disease caused by an inborn deficiency of α-galactosidase A, which results in the progressive accumulation of globotriaosylceramide and other neutral glycolipids in a range of cells and tissues. In association with the renal and cardiac insufficiency, cerebrovascular complications can result in the death of the patients. Several mechanisms causing vascular damage that leads to the development of deep-white matter lesions have been described. Recent clinical trials strongly suggest that statins protect against stroke by neuroprotective properties or pleiotropic effects. Aim: To evaluate evidence and potential beneficial effects of statins in the vasculopathy of Fabry disease.
KeywordsNitric Oxide Simvastatin Homocysteine Tissue Factor Fabry Disease
enzyme replacement therapy
3-hydroxy-3-methylglutaryl coenzyme A
intercellular adhesion molecule-1
nitric oxide synthase
plasminogen activator inhibitor-1
vascular cell adhesion molecule-1
- DeGraba T, Azhar S, Dignat-George F, et al Profile of endothelial and leukocyte activation in Fabry patients. Ann Neurol 2000;47:229–233. doi: 10.1002/1531-8249(200002)47:2<229::AID-ANA13>3.0.CO;2-T.PubMedCrossRefGoogle Scholar
- Iadecola C, Zhang F, Casey R, Nagaiama M, Ross ME. Delayed reduction of ischemic brain injury and neurologic deficit in mice lacking the inducible nitric oxide synthase gene. J Neurosc 1997; 17: 9157–9164.Google Scholar
- Mercuri M, Bond MG, Sirtori CR, et al Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. Am J Med 1996;101:627–634. doi: 10.1016/S0002–9343(96)00333–6.PubMedCrossRefGoogle Scholar
- Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary artery disease. The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–1389.Google Scholar
- Tramontano AF, O’Leary J, Black AD, Muniyappa R, Cutaia MV, El-Sherif N. Statin decreases endothelial microparticle release from human coronary artery endothelial cells: implication for the Rho-kinase pathway. Biochem Biophys Res Commun 2004;320:34–38. doi: 10.1016/j.bbrc.2004.05.127.PubMedCrossRefGoogle Scholar
- Weber C, Erl W, Weber KSC, Weber P. HMG-CoA reductase inhibitors decrease CD11b expression and CD11bdependent adhesion of monocyte to endothelium and reduce increased adhesiveness on monocytes isolated from patients with hypercholesterolemia. JACC 1997; 30: 1212–1217. doi: 10.1016/S0735–1097(97)00324–0.PubMedGoogle Scholar